An Analysis of Medico-Legal Precedents and Ethical Frameworks for Medical Decision-Making

The Shifting Legal Landscape of Patient Consent and Institutional Liability

This article addresses the critical nature of understanding the modern legal framework for informed consent as presented by Irish solicitor and author, Brian Lynch, in his book, ‘Oxygenation is the Solution. Deaths From Covid-19 And Global Legal Insights for Medical Practice: An Insider’s Perspective’.

Let me commence by stating that I’m not a medical doctor, rather I’m an editor and researcher so feel free to take any of my observations on Lynch’s book with a grain of salt! And, of course, visit a physician for medical or health advice. I’m not qualified in this field.

Having stated the above disclaimer, in his book, Lynch’s key point is that recent jurisprudential shifts across the United States, United Kingdom, and Ireland have decisively moved medical decision-making from a physician-centric model to a patient-centric one, creating new and significant liability risks for healthcare institutions. I agree with him on this point. The long-standing principle of “doctor knows best” has (finally) been legally overturned in favour of the patient’s “right to know,” fundamentally altering the legal duties of clinicians and the institutions that employ them.

This article will analyse the core legal principles, ethical mandates, and case law precedents that, according to Lynch, define our new medico-legal landscape. Its purpose is to provide actionable guidance for mitigating these risks through the development of robust institutional policies on patient communication and disclosure.

Lynch argues that failure to adapt to our new legal reality exposes institutions and their clinical staff to litigation based not on clinical error, but on failures in disclosure and communication and, further, an intervention performed with flawless technical skill can still be deemed an unlawful assault if the preceding consent was invalidated by a failure to inform the patient of all reasonable alternative treatments and material risks. This is both an interesting and provocative perspective for him to take.

The Legal Evolution of Informed Consent: From Professional Standard to Patient Autonomy

There’s no doubt that foundational legal principle of informed consent has undergone a radical transformation and understanding this evolution from a standard dictated by medical professionals to one centered on the rights and values of the individual patient is essential for legal counsel, administrators, and clinical leaders to grasp the full scope of their institution’s modern obligations. The following analysis traces the key legal precedents that have reshaped this landscape.

The Foundational Shift: The “Reasonable Patient” Standard

The seminal US case Canterbury v. Spence (1972) fundamentally reshaped medical malpractice law by establishing the patient’s “right to know.” The court determined that a physician’s duty extends beyond skillful diagnosis and therapy to include the obligation to communicate all material risks and reasonable alternatives associated with a proposed treatment.

This ruling established a crucial shift from a professional standard, where disclosure was judged by what a body of medical experts deemed appropriate, to the “reasonable person test.” Under this new standard, the adequacy of disclosure is measured by what a layperson in the patient’s position would want to know to make an informed decision. This patient-centric model places the court, representing the reasonable patient, as the final arbiter of whether a clinician’s disclosure was legally sufficient.

International Jurisprudence: Affirming the Patient-Centered Model

The principles established in the United States have been unequivocally affirmed and adopted in other common law jurisdictions, creating a consistent international legal standard.

United Kingdom: The UK Supreme Court’s 2015 decision in Montgomery v. Lanarkshire Health Board explicitly overturned the long-standing “doctor knows best” principle that had been established by the Bolam case. The court found that a clinician cannot make an objective, purely “medical” view of a patient’s choices and is therefore not in a position to decide what is best for the patient as a matter of clinical judgment alone. The court stated:
Ireland: The Irish High Court’s ruling in Geoghegan v. Harris (2000), later affirmed by the Supreme Court in Fitzpatrick v. White (2007), established the “reasonable person test” in Ireland. These cases affirmed the right of the court, rather than medical experts, to determine the adequacy of disclosure regarding treatment options and their associated risks. This solidified the patient’s role as the ultimate decision-maker in their own care.
The establishment of these legal principles has created clear duties, but we can all see that their application in daily clinical practice presents specific and recurring challenges for healthcare institutions. And they tend to react quite differently.

The Duty of Disclosure: Defining and Communicating “Reasonable Alternative or Variant Treatments”

Lynch argues that the duty to disclose “reasonable alternative or variant treatments” is the most critical and challenging component of modern consent law for healthcare institutions. The interpretation of “reasonable” is not limited to what is considered standard practice but extends to what a patient would find significant.

The Legal Obligation Beyond “Standard of Care”

Lynch states that a common and legally perilous mistake is for clinicians to limit their disclosure to treatments considered “standard of care” or those on approved indication lists (e.g., from the US Food and Drug Administration). The legal duty is broader and includes any scientifically plausible treatment that a reasonable person in the patient’s position would consider significant.

And here’s the core of Lynch’s book. He states Hyperbaric Oxygen Therapy (HBOT) serves as a key case study. Though it is a scientifically established treatment for hypoxic tissue injury, it is often not disclosed for conditions not on narrow, pre-approved lists, leading to potentially invalid informed consent. The legal principle established in the US case The T.J. Hooper is instructive: “a whole calling may have unduly lagged in the adoption of new and available devices.” His key point? An entire field’s failure to adopt a beneficial technology or treatment does not constitute a legal defense if that technology was available and could have produced a better outcome for the patient. Powerful stuff indeed. 

Systemic Barriers to Compliant Disclosure

Several systemic factors create an environment where legally required disclosures are often omitted, exposing institutions to liability.

Over-reliance on Flawed Guidelines: Clinical practice guidelines, such as those from Cochrane Reviews or the European Consensus on Crohn’s Disease, can be legally problematic. If these guidelines use overly narrow inclusion criteria (e.g., demanding only Randomised Controlled Trials) that exclude ethically and scientifically valid treatment options, they can mislead clinicians into believing their disclosure duty is narrower than the law requires. This is a particularly contentious point. 
Regulatory Misinformation: Communications from regulatory bodies can inadvertently create legal risk. A prime example is the US Food and Drug Administration’s “Don’t be Misled” article. The investigative reporting of journalist Duane Pohlman, which highlighted successful uses of HBOT for COVID-19, appeared to influence the FDA to remove the article from its website. Such communications can be legally construed as negligent misrepresentation if they unlawfully dissuade patients and providers from considering viable, scientifically supported treatments, even if those treatments are not yet on an approved list.
Professional and Institutional Inertia: The case of Dr. Michael Neary in Ireland, where a surgeon performed numerous unnecessary hysterectomies over many years, illustrates a catastrophic failure of oversight. The inquiry found that collegiality and a systemic failure to question a consultant’s practices enabled non-compliant and harmful practices to persist, creating massive institutional liability. This serves as a stark warning against passive acceptance of established but questionable practices.
Lynch goes on to state that these barriers must be addressed through the lens of the overarching ethical frameworks that should guide all medical practice.

Ethical Mandates and the Legal Limits of “Evidence-Based” Justifications

A common defense for the non-disclosure of alternative treatments is the perceived lack of “high-quality evidence,” typically defined as large-scale Randomised Controlled Trials (RCTs). However, Lynch suggests this defense is legally and ethically flawed. On this point he has both supporters and detractors as one might expect but he develops his argument.

The Nuremberg Code: The Prohibition on Unnecessary Human Experimentation

The demand for RCTs for treatments with established scientific benefits can violate fundamental medical ethics. The Nuremberg Code, the globally accepted standard for human experimentation, states that an experiment should be:

“...unprocurable by other methods or means of study, and not random and unnecessary in nature.”

As argued by Professor Ruiyong Chen regarding the use of HBOT for COVID-19, it is an ethical violation to place a patient with obvious hypoxia into a control group where they would be deprived of a known beneficial treatment. Insisting on an RCT in such circumstances is not a defense; it is evidence of a failure to adhere to foundational ethical principles.

The “Best Available Evidence at the Time” Standard

In a crisis or when dealing with an individual patient’s unique condition, the legal and ethical standard is not to wait for future trials, but to act on the best evidence available at the time. Ireland’s Ethical Framework for Decision-making in a Pandemic codifies this principle, stating that decisions must be based on the “best clinical evidence available at the time.”

Under this standard, actionable evidence is not limited to RCTs. It includes:

Anecdotal reports and early case series (e.g., n=1 or n=5).
Established scientific principles, such as the universal gas laws that prove the efficacy of hyperbaric oxygenation.
Clinical experience from other jurisdictions.
To withhold disclosure of a treatment supported by this level of evidence while waiting for an RCT is, according to Lynch, to fail the legal duty of care, exposing the institution to significant liability. Failing to adhere to these legal precedents and ethical mandates carries tangible and severe legal consequences. Thoughts on this?

Assessing the Consequences of Non-Compliance: A Risk Analysis

The following material provides a direct risk analysis for administrators and legal counsel, moving from legal theory to the concrete liabilities that arise from failures in the informed consent process. These failures create specific legal claims that can place both individual clinicians and the institution in profound professional and financial jeopardy.

Invalid Consent as Unlawful Assault and Battery

Lynch observes that medical intervention performed without valid informed consent is not merely an act of negligence. Because the consent is legally void due to a failure of disclosure, the physical act of the intervention can be legally defined as an unlawful assault and battery on the patient. This shifts the legal claim from a question of professional standard of care to a more fundamental violation of the patient’s bodily autonomy, carrying severe legal and reputational consequences.

Liability Arising from the Duty of Candour

The legal “duty of candour” is the professional and institutional obligation to openly and honestly disclose when an adverse event has occurred. The principles affirmed in the Irish Supreme Court case Morrissey v. Ireland create a major area of liability when applied to situations like the one described in a report from Irish anaesthesiologists on iatrogenic cerebral artery gas embolism (CAGE). Their report notes that harm from this avoidable event can be mitigated with HBOT. A failure to disclose the availability of a mitigating treatment like HBOT, either before an elective procedure or after the adverse event, constitutes a breach of the duty of candour, creating enduring legal exposure for the institution.

Case Precedent in Direct Liability: Sponenburgh v. County of Wayne

The Sponenburgh case serves as a critical cautionary tale for institutional legal strategy. In this case, a hospital was found liable for $3.08 million for failing to use its available HBOT facility for a patient with carbon monoxide poisoning, resulting in permanent brain injury. The hospital’s defenses were systematically dismantled:

The claim that HBOT was a “fad” was contradicted by medical literature.
The claim that the chamber was for “research only” was impeached by hospital records showing it had been used to treat another patient.
The claim that it was “not standard of care” was deemed irrelevant to the duty to use an available and beneficial treatment.
Crucially, the victim’s lawyers used a local newspaper article, including a photograph of the new chamber with a caption stating it could treat “victims of poison,” as impeachment evidence. This demonstrates that courts will hold institutions directly liable for failing to utilise available, scientifically sound treatments, regardless of whether they are part of a rigid “standard of care” protocol.

Analysing these risks makes it clear that proactive policy change is not optional, but essential for institutional survival in the modern medico-legal environment.

Conclusion: Proactive Disclosure as a Legal Imperative

It seems reasonable to argue that in the current medico-legal environment, a policy of proactive, transparent, and comprehensive disclosure is not merely an ethical ideal but a fundamental legal requirement. Further, the shift from a paternalistic, physician-led model to one centered on patient autonomy is complete and irreversible. Lynch’s argument that Institutions that fail to adapt their policies and culture to this reality are exposed to significant legal, financial, and reputational risk seems logical. Embracing the patient’s “right to know” and ensuring that all reasonable treatment options are discussed is the single most effective strategy for mitigating liability, building patient trust, and upholding the highest standards of both legal compliance and ethical care. And, this is certainly accurate. Let us all have a hand in deciding our own fates.

*©Niall MacGiolla Bhuí, PhD. February 2026.